<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351126</url>
  </required_header>
  <id_info>
    <org_study_id>MSM-01</org_study_id>
    <nct_id>NCT04351126</nct_id>
  </id_info>
  <brief_title>Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response</brief_title>
  <official_title>Pathophysiology and Nature of Ovarian Hyperstimulation Syndrome (OHSS) as a Clinical Entity Could be Fully Explained and Effectively Managed as a State of Defective Mineralocorticoid Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ganin Fertility Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ganin Fertility Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      lines of evidence that support nature of ovarian hyperstimulation syndrome (OHSS) as
      &quot;defective mineralocorticoid response&quot; are cited, our hypothesis is tested clinically in both
      prophylaxis against and treatment of OHSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      several studies state significant correlation between OHSS and activation of
      Renin-angiotensin-aldosterone system (RAAS), degree of activation of RAAS correlates with
      severity of OHSS. In OHSS there is a cascade of events that mainly involves capillary leak
      with resultant fluid shift and electrolytes imbalance, these consequences are more pronounced
      - according to our hypothesis - due to inadequate mineralocorticoid response/activity in
      susceptible individuals in the settings of high progesterone levels with its
      antimineralocorticoid property, OHSS can be interpreted as a (mineralocorticoid deficiency
      crisis) and may effectively be treated as being so, so we conducted this study to test the
      hypothesis in both treatment and prevention of OHSS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of recovery</measure>
    <time_frame>10 days</time_frame>
    <description>Time needed for full clinical recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>prevention of OHSS occurrence</measure>
    <time_frame>21 days</time_frame>
    <description>percentage of cases that has developed OHSS in both control and prevention groups</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients at high risk for OHSS who are receiving conventional treatment either as a prophylaxis (in the form of bromocriptine) or as a management in case of developing OHSS (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient who has developed OHSS while on conventional lines of management (as continual bromocriptine and fluid monitoring and or paracentesis and or tube thoracostomy) patients in this group, fludrocortisone was added to conventional lines of management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prevention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients at high risk for OHSS who are receiving fludrocortisone as a prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone 0.1 Milligrams (mg)</intervention_name>
    <description>0.2-0.6 mg/day of fludrocortisone is prescribed</description>
    <arm_group_label>prevention group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine</intervention_name>
    <description>2.5 mg prescribed Vaginally twice daily</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: patients undergoing ICSI who were considered at risk of developing
        OHSS:

          -  polycystic ovaries and/or previous history of OHSS, AMH &gt; 40 pmol/L but patients were
             finally included in the study if serum E2 levels reached &gt;3000 pg/ml on day of hCG
             trigger or at any stage of folliculometry

          -  age: 18-40

        Exclusion Criteria:

          -  retrieval of less than 20 oocytes

          -  age less than 18 or above 40
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad S Zeafan, MBBCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ganin Fertility Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>khaled M Elqusi, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ganin Fertility Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hossam Elattar, MBBCH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ganin Fertility Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hosam Zaki, MSc, FRCOG</last_name>
    <role>Study Director</role>
    <affiliation>Ganin Fertility Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ganin Fertility Center</name>
      <address>
        <city>Cairo</city>
        <state>Maadi</state>
        <zip>11728</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosler A, Schenker JG. Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril. 1987 Jul;48(1):57-61.</citation>
    <PMID>2439386</PMID>
  </reference>
  <reference>
    <citation>Delbaere A, Bergmann PJ, Englert Y. Features of the Renin-angiotensin system in ascites and pleural effusion during severe ovarian hyperstimulation syndrome. J Assist Reprod Genet. 1997 May;14(5):241-4.</citation>
    <PMID>9147235</PMID>
  </reference>
  <reference>
    <citation>Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014 Jul;4(3):965-94. doi: 10.1002/cphy.c130044. Review.</citation>
    <PMID>24944027</PMID>
  </reference>
  <reference>
    <citation>Dunne FP, Barry DG, Ferriss JB, Grealy G, Murphy D. Changes in blood pressure during the normal menstrual cycle. Clin Sci (Lond). 1991 Oct;81(4):515-8.</citation>
    <PMID>1657498</PMID>
  </reference>
  <reference>
    <citation>Ujioka T, Matsuura K, Kawano T, Okamura H. Role of progesterone in capillary permeability in hyperstimulated rats. Hum Reprod. 1997 Aug;12(8):1629-34.</citation>
    <PMID>9308783</PMID>
  </reference>
  <reference>
    <citation>Lainas T, Petsas G, Stavropoulou G, Alexopoulou E, Iliadis G, Minaretzis D. Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril. 2002 Sep;78(3):529-33.</citation>
    <PMID>12215328</PMID>
  </reference>
  <reference>
    <citation>Kim MK, Won HJ, Shim SH, Cha DH, Yoon TK. Spontaneous ovarian hyperstimulation syndrome following a thawed embryo transfer cycle. Clin Exp Reprod Med. 2014 Sep;41(3):140-5. doi: 10.5653/cerm.2014.41.3.140. Epub 2014 Sep 30.</citation>
    <PMID>25309860</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ganin Fertility Center</investigator_affiliation>
    <investigator_full_name>Muhammad saber mahmoud sayed zeafan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>OHSS</keyword>
  <keyword>Mineralocorticoid</keyword>
  <keyword>aldosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

